Although the rates of BRAF mutation in GB are far lower than in melanoma (8% vs 40%, approximately), in light of the limited therapeutic options available for refractory/relapsing GB and following the success of these drugs in other settings, there is a growing interest in establishing a potential role for B-Raf-inhibitors in this scenario. The gene discussed is BRAF; the disease is melanoma.